Memory loss is an early symptom of Alzheimer's Disease (AD). The findings of Gong et al. (2006) now indicate that enhancing the activity of UCH-L1, a ubiquitin hydrolase, alleviates the synaptic dysfunction and memory loss associated with a mouse model of AD. This work also raises the question of what role UCH-L1 might play in other diseases involving protein aggregation, such as Parkinson's Disease.
of predicted c-Myc binding sites in the genome and its association with histone acetyltransferase complexes prompted the authors to speculate that c-Myc may induce global histone acetylation (Fernandez et al., 2003) , perhaps allowing Oct3/4 and Sox2 to bind to otherwise inaccessible sites. Unlike c-Myc, the role of Klf4 in reprogramming is more likely to be strictly one of transcriptional control. Its key contribution to this process is probably to downregulate the transcription of p53 (Rowland et al., 2005) , which is known to regulate expression of Nanog (Lin et al., 2005) . Repression of p53 also inhibits c-Myc-induced apoptotic pathways (Zindy et al., 1998) , suggesting that c-Myc and Klf4 may act reciprocally and that a finely tuned balance between them could be crucial for successful reprogramming.
Not only does the work of Takahashi and Yamanaka (2006) lend important insight into the molecular nature of reprogramming and pluripotency, it represents a significant step toward a rational approach for generating patient-specific ES cell lines that could be used either as a source of autologous tissue for transplantation or for modeling different diseases. This method is encumbered by neither the logistical constraints nor the societal concerns presented by somatic cell nuclear transfer. However, practical application of this approach still requires answering questions concerning the incomplete nature of the reprogramming observed, the constitutive expression of the transgenes, and the therapeutic utility of cells modified with known oncogenes and oncogenic viral vectors.
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., and Yamanaka, S. (2003) Understanding the molecular mechanism of memory is one of the most compelling and complex challenges for the next generation of scientists. In a paper that appears in this issue, Arancio and colleagues identify a protein that may participate in both normal memory formation and in the type of memory loss characteristic of early AD: the enzyme ubiquitin C-terminal hydrolase of the L1 type (UCH-L1) (Gong et al., 2006) . They show that administration of a UCH-L1 fusion protein to supplement endogenous UCH-L1 has a protective effect on memory loss in a mouse model of AD. Although the authors propose that this effect is mediated by a process involved in normal memory, there is some evidence that UCH-L1 may also be involved in a protective path-way that would also be relevant to other protein aggregation diseases such as Parkinson's disease (PD).
Two primary factors led the authors to focus their efforts on UCH-L1: First, UCH-L1 has a putative but still undefined role in the ubiquitindependent protein degradation pathway. Postmortem analysis of human brains has shown this pathway to be compromised in AD. Second, in the sea slug Aplysia, the expression of a UCH-L1 homolog is increased during long-term facilitation, which is related to synaptic plasticity and learning. The study of Gong et al. was designed to test the proposal that UCH-L1 promotes synaptic plasticity and counteracts memory loss in AD.
The authors examined longterm potentiation (LTP), an experimental model for memory that is widely accepted. LTP is an electrophysiological phenomenon, characteristic of intact neural systems, that depends on synaptic plasticity. Compromised LTP may be a cause of the memory loss that occurs early in the course of AD. Several lines of evidence support the relevance of LTP to AD. LTP deficits are observed in transgenic mouse models of AD. These mice overproduce the amyloid-β protein (Aβ), which is subsequently deposited in the form of amyloid plaques, a characteristic feature of AD. These mice also exhibit age-dependent neurodegeneration and AD-like cognitive deficits. Moreover, in wild-type mice the administration of oligomeric forms of Aβ compromises LTP (Walsh et al., 2002) . Elucidating the sequential relationships between plaque formation, deficits in LTP, cognitive function, and neuronal cell death is critical for the development of breakthrough treatments for AD. Gong et al. provide a new molecular clue by demonstrating that exogenous UCH-L1 reverses a deficit in LTP that is induced by Aβ.
Treatment of hippocampal slices with a small-molecule inhibitor of UCH-L1 enzymatic activity (Liu et al., 2003) produces a deficit in LTP (Gong et al., 2006) as does administration of oligomeric Aβ. To augment endogenous UCH-L1, Gong et al. created a recombinant protein in which UCH-L1 was fused to the transduction domain of the HIV-transactivator protein (TAT) to promote the internalization of the fusion protein into cells. Remarkably, the effect of oligomeric Aβ can be reversed by coadministering a recombinant UCH-L1 protein (Gong et al., 2006) . Similarly, treatment of transgenic mouse models of AD with UCH-L1-TAT restores LTP and contextual memory to normal levels. This treatment decreases levels of the regulatory subunit of protein kinase A (PKA-RIIα), which, in turn, leads to increased levels of phosopho-CREB (cAMP response element binding protein), a transcription factor that promotes synaptic plasticity, LTP, and memory (Gong et al., 2006) . These findings clearly demonstrate a link between UCH-L1 and LTP and suggest that activation of UCH-L1 may be a therapeutic approach to memory loss.
To turn this finding into medicine, it is critical to further investigate its mechanistic basis. It will be very important to determine whether UCH-L1 acts to reverse a single deleterious effect of oligomeric Aβ, or whether it could instead act in a more global way, by destroying or "neutralizing" oligomeric Aβ.
In the latter scenario all of the symptoms of AD that are caused by oligomeric Aβ, not just memory loss, could be targeted by enhancing the relevant activity of UCH-L1. Gong et al. propose that UCH-L1 reverses the inhibitory effect of oligomeric Aβ on LTP by stimulating proteasomal degradation of PKA-RIIα and reducing PKA-RIIα to normal levels (Figure 1 ). This model is based, in part, on the assumption that UCH-L1 plays a role in the proteasomal degradation pathway. However, the linkage of UCH-L1 to the ubiquitin-dependent proteasomal pathway is primarily based on its sequence homology to UCH-L3 and the fact that, in vitro, both are capable of hydrolyzing C-terminal conjugates of ubiquitin (conjugates of other Ub-like proteins may also be substrates). Yet, several differences between UCH-L1 and UCH-L3 suggest that their in vivo activities may be very different. For example, in vitro the ubiquityl hydrolase activity of UCH-L1 is much lower than that of UCH-L3 (Liu et al., 2002; Das et al., 2006) . In addition, the expression of UCH-L1 is much higher in terminally differentiated cells, particularly in the brain, whereas UCH-L3 is highly expressed systemically, including in the brain. One could argue that a "backup" UCH is required because proteasomal degradation is more critical Oligomeric Aβ protein (Αβ42) n has been linked to neurodegeneration and plaque formation. Gong et al. propose that UCH-L1, a ubiquitin C-terminal hydrolase, counteracts the inhibitory effect of oligomeric Aβ on the proteasome by promoting protein degradation in general, including the degradation of PKA-RIIα. Because increased PKA-RIIα is linked to decreased long-term potentiation (LTP), reducing PKA-RIIα would promote a restoration of normal LTP and cognitive function. In an alternative model, UCH-L1 directly promotes the degradation or neutralization of oligomeric Aβ, thus restoring the activity of the proteasome. The pathway involved may be generalizable to other protein aggregates. The link between disruption of LTP and neurodegeneration is uncertain. This is a critical question that may be addressed using transgenic mouse models.
in postmitotic cells, but it is difficult to explain why the absence of UCH-L1, as seen in the gad (gracile axonal dystrophy) mouse, results in neurodegeneration, whereas the absence of UCH-L3 does not (Saigoh et al., 1999; Kurihara et al., 2001) .
It is possible that UCH-L1 influences the proteasome pathway but by a mechanism unrelated to its enzymatic activity. UCH-L1 and an enzymatically inactive mutant, C90S, both increase free ubiquitin levels in cell culture experiments (Osaka et al., 2003) . But C90S-TAT did not rescue the deficit in LTP induced by Aβ, making free ubiquitin levels a less likely explanation for rescue (Gong et al., 2006) . In fact, C90S-TAT acted as a dominant negative, that is, it caused a deficit in LTP in the absence of oligomeric Aβ (Gong et al., 2006) . This striking finding argues that C90S inhibits the protective action of endogenous UCH-L1, which is hard to explain by invoking its hydrolytic activity. A final piece of evidence that is not easily explained by the model proposed by Gong et al. is that, in the absence of oligomeric Aβ, UCH-L1-TAT has no effect on the level of PKA-RIIα. Thus, the pathway that mediates the effect of UCH-L1-TAT seems to be relevant only under conditions induced by protein aggregation.
An alternative model (Figure 1 ) proposes that UCH-L1 rescues the effect of oligomeric Aβ directly, either by promoting its disaggregation, promoting its clearance, or "neutralizing" it in some other way. A recent study showed that the levels in the brain of one oligomeric Aβ species, designated Aβ*56, correlated with the severity of memory deficits of a transgenic mouse (Lesne et al., 2006) . Direct injection of Aβ*56 into a normal mouse induced memory deficits, supporting the proposal that it could be responsible for memory loss. It will be interesting to determine whether Aβ*56 levels are altered in the brains of mice treated with UCH-L1-TAT.
If Aβ*56, for example, is the relevant target of UCH-L1, as opposed to PKA-RIIα, then UCH-L1 may alleviate neuronal degeneration and other phenotypes that characterize full-blown AD. Moreover, one might expect that UCH-L1 could play a role in other protein aggregation-dependent neurodegenerative diseases, such as PD, that are not characterized by early memory loss. In fact, a polymorphism in the UCH-L1 gene that increases the risk of AD in females (Xue and Jia, 2006 ) also effects the risk of PD in Asian populations (Satoh and Kuroda, 2001 ). Thus, it is possible that UCH-L1 is involved in a general neuroprotective response to protein aggregation, rather than an event specific to AD. Irregardless of whether enhancing the activity of UCH-L1 has its beneficial effect in mice by decreasing PKA-RIIα or is instead due to a decrease in oligomeric Aβ, UCH-L1 may prove to be a useful therapeutic target for treating AD.
